Micafungin

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Invasive Fungal Infections

Conditions

Invasive Fungal Infections

Trial Timeline

Mar 1, 2015 → Aug 1, 2015

NCT ID

NCT02678598

About Micafungin

Micafungin is a pre-clinical stage product being developed by Astellas Pharma for Invasive Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT02678598. Target conditions include Invasive Fungal Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03174457	Pre-clinical	Completed	Jun 21, 2017	May 31, 2018	Invasive Fungal Infections
NCT03102658	Approved	Completed	Jan 1, 2017	Jul 1, 2017	Morbid Obesity
NCT02440178	Phase 2	Completed	Sep 19, 2015	Jun 1, 2017	Acute Leukemia
NCT03421002	Phase 2	Completed	May 30, 2015	Apr 10, 2018	Candidiasis, Systemic
NCT02678598	Pre-clinical	Completed	Mar 1, 2015	Aug 1, 2015	Invasive Fungal Infections
NCT02127788	Pre-clinical	Completed	Jul 3, 2014	Jan 27, 2016	Antifungal Prophylaxis
NCT02646800	Approved	Terminated	Mar 21, 2014	Dec 21, 2014	Aspergillosis
NCT02646774	Approved	Terminated	Mar 1, 2014	Jun 26, 2015	Invasive Aspergillosis
NCT02057289	Phase 1	Terminated	Jan 1, 2014	Nov 1, 2014	Immunocompromised
NCT01982071	Approved	Terminated	Sep 26, 2013	Aug 28, 2015	Candidemia
NCT01135589	Approved	UNKNOWN	Apr 1, 2010	May 1, 2012	Neutropenia
NCT00606268	Phase 1	Completed	Nov 1, 2007	Mar 1, 2009	Fungal Infections
NCT00608335	Phase 1	Completed	Oct 14, 2007	Sep 8, 2011	Oropharyngeal Candidiasis
NCT00818584	Phase 1	Completed	Aug 1, 2007	Oct 1, 2007	Candida
NCT00842504	Phase 1	Completed	Jul 1, 2007	Dec 1, 2009	Fungal Infection

Competing Products

20 competing products in Invasive Fungal Infections

See all competitors

Product	Company	Stage	Hype Score
BSG005	Alkem Laboratories	Phase 1/2	41
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	51
Trastuzumab deruxtecan + Durvalumab	Daiichi Sankyo	Phase 2	52
Isavuconazole + Caspofungin + Voriconazole	Astellas Pharma	Phase 3	77
Micafungin + fluconazole	Astellas Pharma	Phase 3	77
Micafungin (Mycamine)	Astellas Pharma	Phase 1	33
Pudexacianinium chloride	Astellas Pharma	Phase 2	52
Enfortumab vedotin + Pembrolizumab	Astellas Pharma	Phase 2	52
Enfortumab Vedotin + Pembrolizumab	Astellas Pharma	Phase 2	52
Isavuconazonium sulfate + Voriconazole + Posaconazole	Astellas Pharma	Pre-clinical	23
Pembrolizumab + Enfortumab Vedotin	Astellas Pharma	Phase 3	77
Isavuconazonium sulfate + Isavuconazonium sulfate	Astellas Pharma	Phase 2	52
Micafungin + Systemic antifungal therapy	Astellas Pharma	Phase 2	52
Micafungin	Astellas Pharma	Pre-clinical	23
Micafungin + Placebo	Astellas Pharma	Phase 3	77
Micafungin	Astellas Pharma	Approved	85
Olorofim + AmBisome®	Shionogi	Phase 3	77
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxel	Jiangsu Hengrui Medicine	Phase 3	77
SHR-A1811 + Trastuzumab Emtansine	Jiangsu Hengrui Medicine	Phase 3	77
Herombopag tablets + Herombopag placebo tablets	Jiangsu Hengrui Medicine	Phase 3	77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved